Canada: Life Sciences, Biotechnology & Nanotechnology

In episode 19, Heather Barnhouse speaks with Kiren Singh, Co-Founder of Haskalife, a Canadian company specializing in developing products from the haskap berry, a superfood native to northern boreal regions.

On April 16, 2025, the Government of Canada issued the "United States Surtax Remission Order (2025)" (the "Remission Order") pursuant to section 115 of the Customs Tariff, which was followed by the release of a customs notice on the application of the Remission Order (the "Customs Notice") by the Canada Border Services Agency.

The federal government has introduced changes to the Food and Drug Regulations[1](the "Regulations") including allowing flexible submission filing...

On April 16, 2025, the Government of Canada issued the "United States Surtax Remission Order (2025)" (the "Remission Order") pursuant to section 115 of the Customs Tariff, which was followed by the release of a customs notice on the application of the Remission Order (the "Customs Notice") by the Canada Border Services Agency.

The ongoing expansion of Neurotechnology (or "neurotech") for consumers is raising questions related to privacy and ownership of one's thoughts, as well as what will happen when technology can go beyond...

The use of artificial intelligence ("AI") in healthcare creates transformational opportunities to improve systems and care, while also testing existing regulatory pathways...

A recent Privacy Complaint (MR21-00090) before the Information and Privacy Commissioner of Ontario (IPC) expanded the scope of what will be considered a privacy breach for Ontario public sector bodies.

On April 10th, 2025, the Ontario government launched a targeted call for proposals to Ontario Health Teams and Indigenous primary health care organizations...

Following are our summaries of the civil decisions of the Court of Appeal for Ontario for the week of April 21, 2025.

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.